The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,296.00
Bid: 11,850.00
Ask: 12,470.00
Change: 0.00 (0.00%)
Spread: 620.00 (5.232%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,296.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: Stocks Mixed Despite Positive Vaccine News

Wed, 30th Dec 2020 11:57

(Alliance News) - Stocks in London were lacking direction on Wednesday midday, amid growing Covid-19 case numbers, and despite Oxford/AstraZeneca vaccine rollout optimism.

The FTSE 100 index was up 4.87 points, or 0.1%, at 6,607.52 on Wednesday. The FTSE 250 index was down 37.98 points, or 0.2%, at 20,859.61 and the AIM All-Share index was up 0.2% at 1,151.80.

The Cboe UK 100 index was up 0.1% at 658.51. The Cboe 250 was down 0.2% at 18,258.70, and the Cboe Small Companies flat at 11,753.33.

In mainland Europe, the CAC 40 in Paris and the DAX 30 in Frankfurt were both flat in the afternoon.

Sterling was quoted at USD1.3600 on Wednesday, jumping from USD1.3509 at the London equities close on Tuesday and reflecting post-Brexit trade deal optimism.

The EU signed the post-Brexit deal on Wednesday, setting it on path to be provisionally implemented after UK Prime Minister Boris Johnson is scheduled to sign it for London in the afternoon.

European Commission President Ursula von der Leyen and European Council chief Charles Michel put their ink on the agreement on Wednesday morning - just a week after the deal had been struck.

The 27 EU ambassadors gave their go-ahead for the provisional application on Tuesday afternoon.

The deal - which provides for zero tariffs and zero quotas between the trading partners - still needs to be ratified by the European Parliament.

The European Commission proposed a period of provisional application until February 28, but this might be extended if the lawmakers are scheduled to give their approval in March.

Also on Wednesday, UK parliament will vote on whether to accept the deal.

The euro traded at USD1.2270, firming from USD1.2246 late Tuesday.

On the LSE, AstraZeneca said its Covid-19 vaccine has been approved for emergency supply in the UK, with the first doses being released on Wednesday so that vaccinations may begin early in the New Year.

FTSE 100-listed Astra shares were up 0.4% on Wednesday midday.

The pharmaceutical firm said it aims to supply millions of doses in the first quarter as part of an agreement with the UK government to supply up to 100 million doses in total.

The vaccine was authorised by the UK Medicines & Healthcare Products Regulatory Agency, recommending two doses administered with an interval of between four and 12 weeks. Clinical trials showed the vaccine to be safe and effective at preventing symptomatic Covid-19, with no severe cases and no hospitalisations more than 14 days after the second dose.

The first doses will be released Wednesday in order for vaccinations to start early in the new year, Astra said.

The vaccine has been approved for the immunization of people aged 18 and over, with the authorisation recommending two doses administered with an interval of four to 12 weeks.

"Key news in the UK is the Oxford/AstraZeneca vaccine authorisation, which brings forward a potential end to further restrictions given the easier logistical and storage requirements. That said, Health Secretary Matt Hancock is expected to announce additional mobility rules within the coming days as cases continue to rise," said Axi analyst Stephen Innes.

More areas in England will be placed under the country's toughest coronavirus restrictions, Health Secretary Matt Hancock is expected to tell the Commons on Wednesday.

Pressure mounted on the government to act as hospitals across England warned of increasing strains on services due to Covid-19 patient numbers, which have reached their highest levels during the pandemic, while 51,135 further cases and 414 deaths were reported on Tuesday.

Johnson chaired a meeting of the government's Covid-19 Operations committee on Tuesday evening, when changes to the tier system were discussed.

With case rates rising in all regions of England, as well as the number of Covid-19 patients in hospitals, any review is likely to involve areas moving up a tier rather than down.

Areas that may be moved from Tier 3 to Tier 4 due to increasing case rates include parts of the East Midlands, such as Northamptonshire and Leicestershire, as well as all areas of the West Midlands metropolitan county.

Hartlepool in north-east England, along with a handful of areas in Lancashire – Blackburn with Darwen, Burnley, Pendle and Ribble Valley – could also be upgraded from Tier 3 to 4.

Back on the LSE, Flutter Entertainment was up 1.2% after saying that completion of the 37% of the issued and outstanding units of FanDuel Group has occurred.

At the end of November, Flutter had entered an agreement with Fastball Holdings to acquire the latter's stake in FanDuel for USD4.18 billion, which will raise Flutter's stake in the fantasy sports, casino and horse racing business to 95% from 59%.

The buy "materially increases exposure to US market", Flutter said at the time, "the most attractive sector opportunity today".

Among the mid-caps, Energean was up 2.1% after reaching an agreement with Kerogen Investments, an affiliate of Kerogen Capital, for the acquisition of Kerogen's 30% shareholding in Energean Israel. This will result in Energean owning 100% of the Israeli business.

A total consideration of between USD380 million and USD405 million, the Mediterranean-focused gas exploration and production company said.

Energean said the acquisition adds 2P reserves of 29.5 billion cubic metres of gas and 30 million barrels of liquids, representing 219 million barrels of oil equivalent in total, to the company.

Taking a 100% interest in Energean Israel will enable Energean to fully control its capital structure, it said, enhancing its ability to maximise total shareholder returns.

Elsewhere, iEnergizer jumped 14% after entering into a credit agreement for a new five-year senior secured term loan facility for USD165 million.

The IT service management company said it intends to utilise the additional financing now available to return cash to shareholders.

Gold was quoted at USD1,880.00 an ounce on Wednesday, slightly lower than USD1,882.29 on Tuesday. Brent oil was trading at USD51.62 a barrel, up on USD51.16 late Tuesday.

The US is called for a higher start, with the Dow Jones and S&P 500 both pointed up 0.4% and the Nasdaq Composite up 0.3%.

Against the yen, the dollar was quoted at JPY103.14, down from JPY103.51.

A quiet economic calendar on Wednesday has the US goods trade balance numbers at 1330 GMT.

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more
2 Feb 2024 06:22

TOP NEWS: US sends drugmakers initial offers in Medicare price talks

(Alliance News) - The US government said it was making initial offers to drugmakers Thursday as part of Medicare negotiations meant to lower the prices many older Americans would pay for 10 medicines.

Read more
1 Feb 2024 15:52

UK earnings, trading statements calendar - next 7 days

Friday 2 February 
YouGov PLCTrading Statement
Monday 5 February 
Home REIT PLCTrading Statement
Porvair PLCFull Year Results
Trident Royalties PLCTrading Statement
Vodafone Group PLCTrading Statement
Tuesday 6 February 
Alumasc Group PLCHalf Year Results
BP PLCFull Year Results
Filtronic PLCHalf Year Results
Mattioli Woods PLCHalf Year Results
Renishaw PLCHalf Year Results
Virgin Money UK PLCTrading Statement
Wednesday 7 February 
Ashmore Group PLCHalf Year Results
Barratt Developments PLCHalf Year Results
HydrogenOne Capital Growth PLCTrading Statement
Phoenix Spree Deutschland LtdTrading Statement
PZ Cussons PLCHalf Year Results
Smurfit Kappa Group PLCFull Year Results
UK Commercial Property REIT LtdTrading Statement
Thursday 8 February 
Anglo American PLCTrading Statement
AstraZeneca PLCFull Year Results
British American Tobacco PLCFull Year Results
Compass Group PLCTrading Statement
Redrow PLCHalf Year Results
SSE PLCTrading Statement
Unilever PLCFull Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
29 Jan 2024 08:19

TOP NEWS: AstraZeneca, Daiichi's Enhertu granted priority review in US

(Alliance News) - AstraZeneca PLC on Monday said its cancer drug conjugate received priority review by the Food & Drug Administration in the US for patients with metastatic HER2-positive solid tumours.

Read more
22 Jan 2024 11:45

BioNTech challenges AstraZeneca with breast cancer precision drug trial

FRANKFURT, Jan 22 (Reuters) - BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

Read more
19 Jan 2024 09:28

TOP NEWS: AstraZeneca's Voydeya receives approval in Japan for PNH

(Alliance News) - AstraZeneca PLC on Friday said its inhibitor Voydeya, also known as danicopan, received approval in Japan for adults with paroxysmal nocturnal haemoglobinuria, or PNH.

Read more
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.